[PDF][PDF] CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought
ME Klein, M Kovatcheva, LE Davis, WD Tap, A Koff - Cancer cell, 2018 - cell.com
ME Klein, M Kovatcheva, LE Davis, WD Tap, A Koff
Cancer cell, 2018•cell.comCDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking
success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist
letrozole in breast cancer, many other combinations have recently entered clinical trials in
multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to
understand the cellular mechanisms by which they act. Here we highlight the mechanisms
by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing …
success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist
letrozole in breast cancer, many other combinations have recently entered clinical trials in
multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to
understand the cellular mechanisms by which they act. Here we highlight the mechanisms
by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing …
CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.
cell.com